

CITATION REPORT

List of articles citing

Circulating endothelial progenitor cells and endothelial function after chronic Tadalafil treatment in subjects with erectile dysfunction

DOI: 10.1038/sj.ijir.3901465

International Journal of Impotence Research, 2006, 18, 484-8

Source: <https://exaly.com/paper-pdf/40448026/citation-report.pdf>

Version: 2024-04-09

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
70	Relationship between chronic tadalafil administration and improvement of endothelial function in men with erectile dysfunction: a pilot study. <i>International Journal of Impotence Research</i> , 2007 , 19, 200-7 ^{2,3}		109
69	O p�is e o endot�lio. Aspectos extra genitais da disfun�� er�til. <i>Revista Internacional De Androlog�a</i> , 2007 , 5, 50-58	0.6	4
68	S�ndrome metab�lica e medicina sexual. Conceitos actuais e avalia�� b�sica. <i>Revista Internacional De Androlog�a</i> , 2007 , 5, 102-106	0.6	
67	Gene therapy for erectile dysfunction. <i>Pharmacogenomics</i> , 2007 , 8, 979-84	2.6	2
66	Current safety and tolerability issues in men with erectile dysfunction receiving PDE5 inhibitors. <i>International Journal of Clinical Practice</i> , 2007 , 61, 1547-54	2.9	20
65	Phosphodiesterase type 5 inhibitors: the day after. <i>European Urology</i> , 2007 , 51, 75-88; discussion 89	10.2	73
64	Relationship between vascular damage degrees and endothelial progenitor cells in patients with erectile dysfunction: effect of vardenafil administration and PDE5 expression in the bone marrow. <i>European Urology</i> , 2007 , 51, 1411-7; discussion 1417-9	10.2	34
63	Daily administration of phosphodiesterase type 5 inhibitors for urological and nonurological indications. <i>European Urology</i> , 2007 , 52, 990-1005	10.2	45
62	[The basics of phosphodiesterase type 5 (PDE5) inhibition in urology]. <i>Der Urologe</i> , 2008 , 47, 1582-7		3
61	Effect of tadalafil on blood flow, pain, and function in chronic cold complex regional pain syndrome: a randomized controlled trial. <i>BMC Musculoskeletal Disorders</i> , 2008 , 9, 143	2.8	34
60	Erectile dysfunction and dyslipidemia: relevance and role of phosphodiesterase type-5 inhibitors and statins. <i>Journal of Sexual Medicine</i> , 2008 , 5, 1066-1078	1.1	38
59	Assessment of endothelial function in the patient with erectile dysfunction: an opportunity for the urologist. <i>International Journal of Impotence Research</i> , 2008 , 20, 370-7	2.3	16
58	The triad: erectile dysfunction--endothelial dysfunction--cardiovascular disease. <i>Current Pharmaceutical Design</i> , 2008 , 14, 3700-14	3.3	85
57	Circulating endothelial progenitor cells in patients with Eisenmenger syndrome and idiopathic pulmonary arterial hypertension. <i>Circulation</i> , 2008 , 117, 3020-30	16.7	184
56	Redefining the role of long-acting phosphodiesterase inhibitor tadalafil in the treatment of diabetic erectile dysfunction. <i>Current Diabetes Reviews</i> , 2008 , 4, 24-30	2.7	9
55	Stem and endothelial progenitor cells in erection biology. <i>International Journal of Impotence Research</i> , 2008 , 20, 243-54	2.3	14
54	Reduced endothelial progenitor cell number and function in inflammatory bowel disease: a possible link to the pathogenesis. <i>American Journal of Gastroenterology</i> , 2009 , 104, 2500-7	0.7	29

53	The challenge of scleroderma ulcers. <i>Journal of Cutaneous Medicine and Surgery</i> , 2009 , 13 Suppl 1, S42-8	1.6	1
52	The PDE5 inhibitor sildenafil increases circulating endothelial progenitor cells and CXCR4 expression. <i>Journal of Sexual Medicine</i> , 2009 , 6, 369-72	1.1	30
51	Isolated polyarteritis nodosa of the genitourinary tract presenting with severe erectile dysfunction: a case report with long-term follow-up. <i>Journal of Sexual Medicine</i> , 2009 , 6, 1189-1193	1.1	3
50	Cardiovascular effects of phosphodiesterase type 5 inhibitors. <i>Journal of Sexual Medicine</i> , 2009 , 6, 658-74	1.1	38
49	Prediction of sexual function after radical prostatectomy. <i>Cancer</i> , 2009 , 115, 3150-9	6.4	31
48	Acute effects of sildenafil on flow mediated dilatation and cardiovascular autonomic nerve function in type 2 diabetic patients. <i>Diabetes/Metabolism Research and Reviews</i> , 2009 , 25, 136-43	7.5	17
47	[Chronic PDE-5 inhibition in patients with erectile dysfunction: new treatment approach using once daily Tadalafil]. <i>Der Urologe</i> , 2009 , 48, 1318, 1320-9		7
46	Effect of vardenafil on endothelial progenitor cells in hypogonadotrophic hypogonadal patients: role of testosterone treatment. <i>Clinical Endocrinology</i> , 2009 , 71, 412-6	3.4	16
45	A new era in the treatment of erectile dysfunction: chronic phosphodiesterase type 5 inhibition. <i>BJU International</i> , 2010 , 105, 1634-9	5.6	26
44	Diabetes, obesity, and erectile dysfunction. <i>Gender Medicine</i> , 2009 , 6 Suppl 1, 4-16		49
43	Phosphodiesterase-5 inhibitors: future perspectives. <i>Current Pharmaceutical Design</i> , 2009 , 15, 3540-51	3.3	33
42	Phosphodiesterase type 5 inhibitors: unmet needs. <i>Current Pharmaceutical Design</i> , 2009 , 15, 3476-85	3.3	25
41	Erectile function rehabilitation in the radical prostatectomy patient. <i>Journal of Sexual Medicine</i> , 2010 , 7, 1687-98	1.1	85
40	Clinical implication of endothelial progenitor cells. <i>Expert Review of Molecular Diagnostics</i> , 2010 , 10, 89-105	3.8	7
39	Endothelial progenitor cells as a new cardiovascular risk factor in Klinefelter's syndrome. <i>Molecular Human Reproduction</i> , 2010 , 16, 411-7	4.4	20
38	Increased osteocalcin-positive endothelial progenitor cells in hypogonadal male patients. <i>Journal of Endocrinological Investigation</i> , 2010 , 33, 439-42	5.2	7
37	Current perspective of pathophysiological and interventional effects on endothelial progenitor cell biology: focus on PI3K/AKT/eNOS pathway. <i>International Journal of Cardiology</i> , 2010 , 144, 350-66	3.2	77
36	Penile rehabilitation after prostate cancer treatment: outcomes and practical algorithm. <i>Urologic Clinics of North America</i> , 2011 , 38, 105-18	2.9	19

35	Effects of phosphodiesterase type 5 inhibitors on endothelial function and cardiovascular autonomic nerve function in men. <i>Journal of Men's Health</i> , 2011 , 8, 109-118	1.2	2
34	Cellular biomarkers of endothelial health: microparticles, endothelial progenitor cells, and circulating endothelial cells. <i>Journal of the American Society of Hypertension</i> , 2012 , 6, 85-99		144
33	Chronic PDE-5 inhibition in patients with erectile dysfunction - a treatment approach using tadalafil once-daily. <i>Expert Opinion on Pharmacotherapy</i> , 2012 , 13, 1481-94	4	15
32	Circulating endothelial progenitor cells and endothelial microparticles in patients with arterial erectile dysfunction and metabolic syndrome. <i>Journal of Andrology</i> , 2012 , 33, 202-9		29
31	Effects of once-daily tadalafil on treatment satisfaction, psychosocial outcomes, spontaneous erections, and measures of endothelial function in men with erectile dysfunction but naive to phosphodiesterase type 5 inhibitors. <i>Journal of Andrology</i> , 2012 , 33, 1305-22		11
30	Endothelial progenitor cells and erectile dysfunction: a brief review on diagnostic significance and summary of our experience. <i>Aging Male</i> , 2013 , 16, 29-32	2.1	14
29	PDE5 inhibitors: considerations for preference and long-term adherence. <i>International Journal of Clinical Practice</i> , 2013 , 67, 768-80	2.9	73
28	Phosphodiesterase type 5 inhibitors improve endothelial function and may benefit cardiovascular conditions. <i>American Journal of Medicine</i> , 2013 , 126, 192-9	2.4	25
27	Vascular regenerative therapies for the treatment of erectile dysfunction: current approaches. <i>Andrology</i> , 2013 , 1, 533-40	4.2	20
26	Advances in Stem Cell Therapy for Erectile Dysfunction. 2014 , 2014, 1-20		5
25	Erectile Dysfunction in Inflammaging. 2014 , 287-295		1
24	DPP-4 inhibition improves a sexual condition?. <i>Medical Hypotheses</i> , 2015 , 85, 124-6	3.8	5
23	Dual Strategy With Oral Phosphodiesterase Type 5 Inhibition and Intracavernosal Implantation of Mesenchymal Stem Cells Is Superior to Individual Approaches in the Recovery of Erectile and Cavernosal Functions After Cavernous Nerve Injury in Rats. <i>Journal of Sexual Medicine</i> , 2016 , 13, 1-11	1.1	19
22	Endothelial progenitor cells, defined by the simultaneous surface expression of VEGFR2 and CD133, are not detectable in healthy peripheral and cord blood. <i>Cytometry Part A: the Journal of the International Society for Analytical Cytology</i> , 2016 , 89, 259-70	4.6	41
21	Molecular mechanisms associated with diabetic endothelial-erectile dysfunction. <i>Nature Reviews Urology</i> , 2016 , 13, 266-74	5.5	67
20	Endothelial progenitor cells (EPCs) in ageing and age-related diseases: How currently available treatment modalities affect EPC biology, atherosclerosis, and cardiovascular outcomes. <i>Mechanisms of Ageing and Development</i> , 2016 , 159, 49-62	5.6	31
19	Lower urinary tract symptoms/benign prostatic hypertrophy and vascular function: Role of the nitric oxide-phosphodiesterase type 5-cyclic guanosine 3',5'-monophosphate pathway. <i>International Journal of Urology</i> , 2017 , 24, 412-424	2.3	6
18	Tadalafil, a long acting phosphodiesterase inhibitor, promotes bone marrow stem cell survival and their homing into ischemic myocardium for cardiac repair. <i>Physiological Reports</i> , 2017 , 5, e13480	2.6	19

17	Urine miR-21-5p as a potential biomarker for predicting effectiveness of tadalafil in benign prostatic hyperplasia. <i>Future Science OA</i> , 2018 , 4, FSO304	2.7	3
16	Endothelial Progenitor Cells: Properties, Function, and Response to Toxicological Stimuli. 2018 , 130-182		2
15	Stem cell and gene-based approaches for cardiac repair. 2018 , 31-96		0
14	Management of cardiovascular complications in Klinefelter syndrome patients. <i>Expert Review of Endocrinology and Metabolism</i> , 2019 , 14, 145-152	4.1	3
13	Phosphodiesterase 5 Inhibitor Use in Patients Undergoing Decompression Surgery for Lumbar Spinal Stenosis. <i>American Journal of Physical Medicine and Rehabilitation</i> , 2021 ,	2.6	
12	Use of Li-ESWT, Tadalafil, and a Vacuum Device to Preserve Erectile Function in Subjects Affected by Peyronie's Disease and Undergoing Grafting Surgery. <i>Uro</i> , 2021 , 1, 187-194		
11	Mobilisation of endothelial progenitor cells: one of the possible mechanisms involved in the chronic administration of melatonin preventing erectile dysfunction in diabetic rats. <i>Asian Journal of Andrology</i> , 2012 , 14, 481-6	2.8	24
10	Stem cells: novel players in the treatment of erectile dysfunction. <i>Asian Journal of Andrology</i> , 2012 , 14, 145-55	2.8	30
9	Endothelium as a Therapeutic Target in Diabetes Mellitus: From Basic Mechanisms to Clinical Practice. <i>Current Medicinal Chemistry</i> , 2020 , 27, 1089-1131	4.3	15
8	Therapeutic Potential of Phosphodiesterase Inhibitors for Endothelial Dysfunction- Related Diseases. <i>Current Pharmaceutical Design</i> , 2020 , 26, 3633-3651	3.3	3
7	Tadalafil treatment had a modest effect on endothelial cell damage and repair ability markers in men with erectile dysfunction and vascular risk. <i>Asian Journal of Andrology</i> , 2014 , 16, 290-4	2.8	7
6	Systemic and metabolic effects of PDE5-inhibitor drugs. <i>World Journal of Diabetes</i> , 2010 , 1, 3-7	4.7	19
5	Erectile Function Preservation and Rehabilitation. 2009 , 139-162		
4	Erectile Function Preservation for Men with Cancer. 2011 , 657-673		
3	Vascular Erectile Dysfunction. 2014 , 1-39		
2	Vascular Erectile Dysfunction. 2015 , 3887-3915		
1	Restorative therapy clinical trials for erectile dysfunction: a scoping review of endpoint measures.		0